Neurodegeneration

Athira Pharma Provides 2023 Pipeline Outlook

Retrieved on: 
Thursday, January 5, 2023
ACT, Dementia, MET, Food, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Neuropathic pain, Lewy body, Hepatocyte growth factor, ALS, Patient, Therapy, IND, HGF, Athira Pharma, Open-label trial, Pharmaceutical industry, Fine chemical, Health insurance, Risk management, Neurotherapeutics

BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023.

Key Points: 
  • Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects
    BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023.
  • This includes our recently published preclinical results in the peer-reviewed journal, Neurotherapeutics, supporting the potential of fosgonimeton,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira Pharma.
  • Athira enrolled 28 patients in the exploratory Phase 2 SHAPE study of fosgonimeton in participants with Parkinson’s disease dementia or Dementia with Lewy bodies.
  • ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS.

Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives

Retrieved on: 
Wednesday, January 4, 2023
Management, Drug discovery, Disclosure, Neurological disorder, Disease, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Machine learning, Therapy, Conference, Neurodegeneration, Pharmaceutical industry

CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Key Points: 
  • CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.
  • The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning.
  • Today, Vyant Bio announced that it has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value.
  • In addition, the Company announced that it is participating in BIO’s One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.

Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Microglia, Conference, Neurodegeneration, PT, Pharmaceutical industry, Online shopping

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m.
  • ET.
  • To access a live webcast of these presentations, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com .
  • An archived replay for each will be available for approximately 90 days following the presentation.

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

Retrieved on: 
Thursday, December 29, 2022
Multiple, Multiple sclerosis, BTK, MD, Clinical trial, MS, Neurology, ANSM, Disease, Patient, NSPM, Microglia, B cell, Veni, vidi, vici, FOOD, Safety, Pathology, University, FDA, EDSS, PPMS, University of Lille, DRUG, Cell, Neurodegeneration, Randomness, Pharmaceutical industry, Masitinib

AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS

Key Points: 
  • AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS
    This decision follows authorizations received from several European countries, including the French Agency (ANSM).
  • This is a randomized, double-blind, Phase 3 study to evaluate the safety and efficacy of masitinib 4.5 mg/kg/day in patients with primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (nSPMS).
  • The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression.
  • Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco

Retrieved on: 
Wednesday, December 28, 2022
U.S. Summit Company, Precision medicine, Drug discovery, Neurodegeneration, Fierce, Pharmaceutical industry

and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.
  • The Company will also be attending the Fierce JPM Week.
  • CENTOGENE will meet with potential partners and investors to discuss the Company’s strategic developments aimed at providing data-driven, life changing answers to accelerate and de-risk drug discovery & development for the commercialization of precision medicine.
  • Please see additional details below:

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Retrieved on: 
Tuesday, December 27, 2022
COVID-19, Mitt, SALT, CNM, Zinc, Patient, Silver, Safety, PCR, COVID, Neurodegeneration, Pharmaceutical industry

The Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of CNM-ZnAg in COVID-19 infected participants in Brazil.

Key Points: 
  • The Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of CNM-ZnAg in COVID-19 infected participants in Brazil.
  • Study participants were randomized 1:1:2 to receive daily low dose CNM-ZnAg, high dose CNM-ZnAg, or placebo in addition to standard supportive care for up to 21 days.
  • We are heartened by the safety profile of CNM-ZnAg, the second asset developed through our technology platform, and its future potential in other antiviral and antibacterial areas.
  • We continue our focus on treatment of neurodegenerative diseases with our lead asset, CNM-Au8, which is advancing towards registrational trials.”

CENTOGENE Reports Second Quarter and First Half 2022 Financial Results

Retrieved on: 
Thursday, December 22, 2022
EBITDA, WES, Ministry, USD, Genetic testing, Growth, Classification, Supervisory board, Materiality, Agios Pharmaceuticals, Ministry of Health (Saudi Arabia), Gaucher's disease, Niemann–Pick disease, Research, Audit committee, Total, Lumpy skin disease, Software as a service, COVID, Partnership, Mass meeting, COVID-19, Tax, WGS, EUR, Core business, Collection, Software, Ageing, Neurodegeneration, CFO, Disease, Patient, IVD, Turtle excluder device, Diagnosis, Whole genome sequencing, Marketing, European, Renewable energy, Video game, Fine chemical, Cryptocurrency, Pharmaceutical industry, Vaccine, Bank, Construction, Medical device, Bookkeeping, Health, Pharma

and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the second quarter and first half ended June 30, 2022 and updated its fiscal year 2022 financial outlook.
  • Revenues from our new collaborations totalled €298 thousand and €329 thousand, respectively, for the second quarter and first half of 2022.
  • There were no impairment expenses for financial assets incurred for the second quarter and first half of 2022 as compared to €544 thousand and €615 thousand, respectively incurred for the second quarter and first half of 2021.
  • The gain on reversal of financial asset impairment for the second quarter and first half of 2022 was €1,035 thousand and €919 thousand, respectively.

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Retrieved on: 
Wednesday, December 21, 2022
Oxidative stress, Excitotoxicity, Mouse, Doctor of Philosophy, Neurotoxicity, Memory, Neurodegeneration, Government budget balance, Research, Patient, RATS, Learning, LPS, Neuron, Athira Pharma, Degenerative disease, HGF, Pharmaceutical industry, Dementia, Neurotherapeutics

BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models.

Key Points: 
  • BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models.
  • The article titled, “Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia,” was published online on December 20, 2022 in the peer-reviewed journal, Neurotherapeutics.
  • "This publication adds to the growing body of preclinical evidence demonstrating that enhancing the HGF/MET neurotrophic system with fosgonimeton may have therapeutic benefit for dementia and other neurodegenerative diseases,” said Kevin Church, Ph.D., Executive Vice President, Research of Athira Pharma.
  • “These data demonstrate that treatment with fosgonimeton or its active metabolite, fosgo-AM, protects cortical neurons challenged with neurotoxic insults that mimic critical aspects of neurodegeneration.

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

Retrieved on: 
Wednesday, December 21, 2022
ESS, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, Orphan, Clinical Global Impression, Glycogen storage disease, KMPH, CNS, IHSS, Disease, Idiopathic hypersomnia, Patient, Safety, Somnolence, FDA, Therapy, IH, SDX, Neurodegeneration, Pharmaceutical industry, Medical imaging

CELEBRATION, Fla., Dec. 21, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare CNS, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder. KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate. SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.

Key Points: 
  • KP1077 is comprised solely of serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate.
  • SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.
  • The Phase 2 clinical trial is a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center study evaluating the efficacy and safety of KP1077 for the treatment of IH.
  • KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2022

Retrieved on: 
Sunday, January 8, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, NanoString Technologies, National Geographic, Research, Wake Forest, Neurodegeneration, Publication, Total, Growth, SMI, DSP, Nature Biotechnology, RNA, Video game, Microscope

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the fourth quarter and fiscal year ended December 31, 2022.

Key Points: 
  • NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the fourth quarter and fiscal year ended December 31, 2022.
  • “NanoString continued to build on our strong spatial biology franchise in 2022, capturing a record 105+ new system orders in the fourth quarter, bringing growth in spatial biology system orders to 50% for the full year,” said Brad Gray, President and CEO of NanoString.
  • “We shipped our first CosMx systems to customers in December, and our CosMx order backlog of approximately $40 million at year end provides the foundation for revenue growth in 2023.”
    Secured customer orders for more than 105 spatial biology systems in Q4, including approximately 80 for CosMx™ Spatial Molecular Imagers (SMI) and over 25 for GeoMx Digital Spatial Profilers (DSP), an increase of 50% as compared to 2021 for both the fourth quarter and full year 2022
    CosMx SMI highlighted on the cover of the December 2022 issue of Nature Biotechnology, demonstrating high-resolution, single cell imaging of RNA and protein
    CosMx SMI featured in the January 2023 issue of National Geographic.
  • Researchers at Wake Forest used CosMx to perform high-resolution imaging of brain tissue in their ongoing Alzheimer’s research.